We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.
W e observed a 69-year-old retired male, whose father suffered from HLA B27-positive ankylosing spondylitis, with persistent night back pain and alternating episodes of sciatica. He improved on etoricoxib 90 mg/daily but experienced three episodes of elevated blood pressure. HLA B27 typing was positive. Radiographs of the spine showed the presence of bone bridge sindesmophytes and sclerosis of the vertebral somatic limits. Magnetic resonance showed a cancellous osteitis of L2, L3, and L4 involving the somatic edges of the vertebral body. Contrast enhancement was seen of the central part of the L2-L3, L3-L4, and L4-L5 discs, of the postero-lateral left paraspinal area, and of the left paravertebral venous plexus. Sacroiliitis with bone edema was also present. Blood coltures were negative for yersinia, brucella, streptococcus and staphylococcus; Salmonella paratyphy B serodiagnosis was positive, probably indicating natural infection or prior vaccination. Mantoux test and Quantiferon were negative. Routine blood examination showed erythrocyte sedimentation rate 49 mm/h (n.v. <20 mm/h), C-reactive protein 1.31 mg/dL (n.v. <0.5 mg/dL), interleukin-6 4.1 pg/mL (n.v. <3.2 pg/mL), and tumor necrosis factor a 17.3 pg/mL (n.v. <15.6 pg/ mL). ASDAS activity score was 2.4. 
Radiological vignette

ally been described in association with spondylodiscitis in AS (2) . The frequency of aseptic discitis in patients with AS is probably overestimated as a result of inclusion of degenerative lesions but also because of exclusion bias. The prevalence of destructive lesions varies between 1% and 28% (2, 3) . In spite of the findings in our patient, the positive predictive value of 18F-NaF PET for diagnosing spondyloarthritis or predicting a response to TNF antagonist therapy seems to be inconsistent (4) . 
